Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
Lupin’s world class manufacturing facilities are spread across India, Japan, USA, Mexico and Brazil.
These 18 facilities benchmarked to international standards are set up to meet stringent quality standards, playing a critical role in achieving our global growth aspirations.
All our facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa.
Research and Development (R&D) forms an integral part of our business strategy. With research and development sites across the globe, our recent R&D endeavour have led to significant progress in many areas including New Chemical Entity (NCE) program. Additionally, our foray into the Advanced Drug Delivery Systems (ADDS) has resulted in platform technologies that are used to develop value-added generic pharmaceuticals.
Lupin is headquartered in Mumbai (India). It is listed on the National Stock Exchange (NSE) as well as the Bombay Stock Exchange (BSE) and has a presence on the Bloomberg and Reuters terminals.
With a patient-first approach, Lupin is transforming the pharmaceutical industry to find novel ways of utilizing technology and research to focus on high-quality and affordable medicines, not just for few but to many across the globe.
BSC : 500257
NSE : LUPIN
RETURNS : LUPIN.BO
BLOOMBERG : LPC IN